期刊文献+

“解郁胶囊”治疗抑郁症临床研究 被引量:2

在线阅读 下载PDF
导出
摘要 目的:观察解郁胶囊治疗抑郁症的疗效和安全性。方法:采用随机双盲双模拟方法将200例患者随机分为2组,实验组口服解郁胶囊,4粒/次,3次/d,对照组口服度洛西汀,20~40mg/d。2组病例均于入院、治疗0、2、4、6周时分别计算汉密尔顿焦虑量表(HAMA)以及汉密尔顿抑郁量表(HAMD)总分及治疗后的减分率。结果:2组患者(HAMD)以及(HAMA)总分在治疗结束时均显著下降(P<0.01)。2组之间疗效无显著性差异(P>0.05),治疗结束时HAMA减分率分别为解郁胶囊组(0.738±0.236),度洛西汀组(0.741±0.210)(P>0.05);有效率解郁胶囊组79.4%,度洛西汀组为85.4%(P>0.05)。解郁胶囊组不良反应发生频率显著低于度洛西汀组,主要是消化系统不良反应,解郁胶囊的疗效指数也显著高于度洛西汀组。结论:解郁胶囊是一种安全有效的抗抑郁药。
出处 《甘肃中医》 2009年第8期31-33,共3页 Gansu Journal of Traditional Chinese Medicine
基金 2006年度甘肃省中医药科研课题(编号GZK-2006-38)
作者简介 石洲宝(1962-),男,主治医师,在职硕士研究生。研究方向:中西医结合神经医学。
  • 相关文献

参考文献14

  • 1张明圆.精神科评定量表[M].长沙:湖南科技出版社,1993.15-25.
  • 2庞天鉴.DSM-IV分类与诊断标准[S].西安:杨森出版局,2001:161-166.
  • 3陈彦方.中国精神障碍诊断与分类标准[S].济南:山东科学技术出版社,2001:56-66.
  • 4Richsrd C, Shelton RC, Gary D, et al. Anovel augmentation strategy for treating resistant major depression[J].Am J Psychatry, 2001 (158):131-134.
  • 5Zisook SL,Stewart JW. Effect of age at onset on the course a major depressive disorder[J]. Am J Psychitry, 2007(164): 1539-1546.
  • 6McIntyre A, Gendron A,McIntyre A. Quetiapine reduces residual depressive and prominent anxiety symptoms in partial responders to selective serotonin reuptake inhibitrors (SSRLs)or serotonin norepine-phrine reuptake inhibitors(NRLs) with major depression and 8 week doubleblind randomized placebo controlled study [J].Euro Psychiatry, 2006,21(suppl 1)164.
  • 7Calabrese JR, Keek PE, Macfadden W, et al.A randomized double-blind, placebo-controlled trial of quetiapine in the treatment of ipolar Ior Ⅱ depression[J].Am J Psyxhiantry, 2005(62):1351-1360.
  • 8路英智,任清涛,田明萍.帕罗西汀与帕罗西汀合用利培酮治疗抑郁症的疗效比较[J].中国神经精神疾病杂志,2003,29(2):138-138. 被引量:7
  • 9Holtzer R, Scarmeas N, Wegesin DJ, et al. Depressive symptoms in Alzheimer's disease:natural course and temporal relation to function and cognitive status[J], J Am Geriatr Soc, 2005(53):2083-2089.
  • 10McIntyre A,Gendron A,Mclntyre A. Queti apiine to select serotonin reuptake in hibitors or venlafaxine in patients with major depression comorbid anxiety and residula depressive symptons, a randomized placebo-controlled polot study[J].Depress Anxiety,2007(24):487-497.

二级参考文献22

  • 1[1]Rothschild AJ. Management of psychotic, treatment-resistant depression.Psychiatr Clin North Am, 1996, 19(2) :52.
  • 2[2]Bersani G and Pozzi F. 5-HT2 receptor antagomsin in dysthymic disorder.Acta Psychiatr Scand,1991, 83(4) :8.
  • 3[3]Tollefscn GD. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry, 1998, 43( 11 ):10.
  • 4Abdelhamid S,Muller-Lobeck H,Pahl S,et al.Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients.Arch Intern Med,1996,156:1190-1195.
  • 5Kaplan NM.Resistant hypertension.Hypertension,2005,23:1441-1444.
  • 6Lorena M,Cristian C,Alexis G,et al.Primary aldosteronism.Hypertension,2003,42:161-165.
  • 7Hiramatsu K,Yamada T,Yukimura Y,et al.A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity.Results in hypertensive patients.Arch Intern Med,1981,141:1589-1593.
  • 8Fardella CE,Mosso L,Gomez-Sanchez C,et al.Primary hyperaldosteronism in essential ypertensives:prevalence,biochemical profile,and molecular biology.J Clin Endocrinol Metab,2000,85:1863-1867.
  • 9Mulatero P,Stowasser M,Loh KC,et al.Increased diagnosis of primary aldosteronism,including surgically correctable forms,in centers from five continents.J Clin Endocrinol Metab,2004,89:1045-1050.
  • 10Nishizaka MK,Pratt-Ubunama M,Zaman MA,et al.Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.Am J Hypertens,2005,18:805-812.

共引文献77

同被引文献15

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部